1. Molekulyarnye markery v diagnostike myshechno-neinvazivnogo raka mochevogo puzyrya / P.V. Glybochko [i dr.] // Klin. lab. diagnostika. - 2011. - № 5. - S. 16-20.
2. Onkomarkery v diagnostike stadii invazii raka mochevogo puzyrya / A.N. Ponukalin [i dr.] // Med. vestnik Bashkortostana. - 2013. - T. 8, № 2. - S.213-217.
3. Tarasov, N.I. Primenenie mochevogo markera UBC (urinary bladder cancer antigen) v diagnostike retsidivov raka mochevogo puzyrya posle TUR / N.I. Tarasov, D.V. Gumenetskii // Ural. med. zhurn. - 2009. - № 4. - S. 122-126.
4. Urinarnyi i syvorotochnye tsitokeratiny v rannei diagnostike raka mochevogo puzyrya / E.V. Ryazantsev [i dr.] // Vestnik RNTsRR MZ RF. - 2011. - № 11. - S. 283-292.
5. Bladder cancer screening with urine-based tumour markers - occupational medical experience / M. Nasterlack [et al.] // Aktuelle urologie. - 2011. - Vol. 42, № 2. - P. 128-134.
6. Clinical usefulness of CEA, CA19-9, andCYFRA21-1 as tumormarkers for urothelial bladder carcinoma / S. Washino [et al.] // Urol. Int. - 2011. - Vol. 87, № 4. - P. 420-428.
7. Comparative analysis of sensitivity to blood in the urine for urine-based point-of-care assays (UBC rapid, NMP22 Bladder Chek andBTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on the results of urine-based POC tests/ G. Ludecke [et al.] // Anticancer Res. - 2012. - Vol. 32, № 5. - P. 2015-2018.
8. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer / S. Jeong [et al.] // Clin. Chim.- 2012. - Vol. 414. - P. 93-100.
9. Influencing factors on theNMP-22 urine assay: an experimental model / M. Miyake [et al.] // BMC Urol. - 2012. -Vol. 12. - P. 23.
10. NMP-22, urinary cytology and cystoscopy: a 1 year comparison study / A. Schlake [et al.] // Can. J. Urol. - 2012. - Vol. 19, № 4. - P. 6345-6350.
11. Prognostic significance of preoperative serum CYFRA21-1 in patients with upper urinary tract urothelial carcinoma / T. Suyama [et al.] // Int. J. Urol. - 2011. - Vol. 18, № 1. - P. 43-47.
12. Prognostic value of tissue-polypeptide specific antigen (TPS) in bladdercancer/ V. Menendez Lopez [et al.] // Anticancer Res. - 2002. - Vol. 22, № 6. - P. 3713-3716.
13. Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors / A. Di Carlo [et al.] // Int. J. Oncol. - 2003. - Vol. 23, № 3. - P. 757-762.
14. Use of the NMP22 Bladder Chek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study / E.C. Hwang [et al.] // Urology. - 2011. - Vol. 77, № 1. - P. 154159.
Email this article 